InsideArbitrage Event Driven Monitor – April 1, 2026

Key Takeaways

• Lilly pays $6.3B, 38% cash premium for Centessa
• Biogen offers $5.6B, 140% premium for Apellis
• Fidelity acquires Affinity Bancshares for $143M, 17% premium
• Activist pushes Snap to exceed $26 share price
• Insider purchases across biotech, tech signal confidence

Summary

Eli Lilly announced a $6.3 billion cash‑plus‑contingent‑value‑right acquisition of Centessa Pharmaceuticals, paying a 37.8% premium, while Biogen launched a $5.6 billion tender offer for Apellis at a 140% premium. Fidelity BancShares agreed to buy Affinity Bancshares for $142.8 million, offering a 17.3% premium, and several other deals—including United Homes, SkyWater Technology and DigitalBridge—are slated for completion in 2026. Activist investors are targeting Snap and Teladoc, and a wave of insider purchases spans biotech, fintech and semiconductor firms. Lender groups also revised terms on a $7.2 billion Sealed Air financing.

Pulse Analysis

The biotech merger wave is accelerating as Eli Lilly and Biogen each commit multibillion‑dollar cash offers that dwarf typical industry premiums. Lilly’s acquisition of Centessa, structured with a $38 per share cash payment and a contingent value right up to $9 per share, reflects a strategic bet on sleep‑wake disorder treatments. Biogen’s tender for Apellis, delivering a $41 cash price and an additional CVR, signals a aggressive expansion into immunology and rare‑disease pipelines. Such premium pricing not only reshapes competitive dynamics but also tightens the arbitrage spread for traders monitoring deal risk and regulatory clearance timelines.

Meanwhile, activist investors are re‑energizing boardroom battles, most notably at Snap, where Irenic Capital seeks operational reforms to lift the stock above $26. In parallel, Pineal Capital’s push for cost cuts and a possible breakup of Teladoc’s Integrated Care and BetterHelp units illustrates how shareholder pressure can catalyze strategic pivots. Insider buying across sectors—from Mineralys Therapeutics to Taiwan Semiconductor—adds another layer of market sentiment, suggesting confidence in long‑term growth despite short‑term volatility.

Beyond individual transactions, the broader merger‑arbitrage landscape is shaped by ancillary moves such as share‑repurchase authorizations by Cimpress and nCino, a reverse‑Morris‑Trust spinoff by Unilever with McCormick, and regulatory scrutiny of DigitalBridge’s SoftBank acquisition by the European Commission. Investors should track deal‑specific milestones, premium structures, and the evolving activist climate to gauge risk‑adjusted returns in a year marked by both high‑value consolidations and heightened governance activism.